2021年欧洲白血病感染会议(ECIL 9)关于血液系统恶性肿瘤或造血细胞移植患者COVID-19管理的建议
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)自2019年起全球传播并导致COVID-19大流行。该病毒感染以初始病毒期、部分患者继而出现严重炎症期为特征,免疫功能受损患者病毒期可能延长、排毒数月而炎症期缺失或失调。血液病患者中,COVID-19在急性白血病、高危骨髓增生异常综合征及造血细胞移植和嵌合抗原受体T细胞治疗后与高死亡率相关,症状体征与总体人群相似但严重程度和结局更差。
要点
- SARS-CoV-2阳性患者推荐推迟免疫清除性细胞治疗。
- 诊断金标准为鼻咽拭子核酸检测病毒RNA,快速抗原检测敏感性较低,尤其无症状患者。
- 预防基于针对气溶胶-飞沫-接触传播的严格感染控制措施。
核心结论
- 血液病患者COVID-19症状体征与总体人群相似,但严重程度和结局更差。
- SARS-CoV-2阳性患者推荐推迟免疫清除性细胞治疗,其他高危病例的血液学治疗决策须权衡个体风险与获益。
- 所有预防和治疗措施在血液病患者中的获益需进一步研究。
研究设计与样本
- 2021年欧洲白血病感染会议(ECIL 9)制定的管理建议。
主要发现
- COVID-19在急性白血病、高危骨髓增生异常综合征以及造血细胞移植和嵌合抗原受体T细胞治疗后与高死亡率相关。
- 免疫受损患者病毒期可能延长,排毒数月,炎症期缺失或失调。
- 鼻咽拭子核酸检测病毒RNA敏感性高、特异性高;快速抗原检测敏感性较低,尤其无症状患者。
- SARS-CoV-2疫苗在总体人群中高效减少社区传播、住院和重症COVID-19死亡,但免疫抑制/血液病患者疫苗血清应答可能较低。
- 新变异株出现可能需疫苗修改及提高脆弱患者疗效的策略。
关键数值与推荐
- SARS-CoV-2阳性患者推荐推迟免疫清除性细胞治疗。
- 诊断金标准为鼻咽拭子样本核酸检测病毒RNA。
- 预防基于针对气溶胶-飞沫-接触传播的严格感染控制措施。
- 特异性治疗针对病毒复制控制(抗病毒药、抗刺突单克隆抗体),需要时控制炎症(地塞米松、抗IL-6药物等)。
临床怎么用
- SARS-CoV-2阳性血液病患者推荐推迟免疫清除性细胞治疗。
- 其他高危病例的血液学治疗决策须权衡个体风险与获益。
- 诊断采用鼻咽拭子核酸检测病毒RNA;快速抗原检测敏感性较低。
- 预防采用针对气溶胶-飞沫-接触传播的严格感染控制措施。
局限性
- 所有预防和治疗措施在血液病患者中的获益需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS-CoV-2 infection is characterised by an initial viral phase followed in some patients by a severe inflammatory phase. Importantly, immunocompromised patients may have a prolonged viral phase, shedding infectious viral particles for months, and absent or dysfunctional inflammatory phase. Among haematological patients, COVID-19 has been associated with high mortality rate in acute leukaemia, high risk-myelodysplastic syndromes, and after haematopoietic cell transplant and chimeric-antigen-receptor-T therapies. The clinical symptoms and signs were similar to that reported for the overall population, but the severity and outcome were worse. The deferral of immunodepleting cellular therapy treatments is recommended for SARS-CoV-2 positive patient, while in the other at-risk cases, the haematological treatment decisions must be weighed between individual risks and benefits. The gold standard for the diagnosis is the detection of viral RNA by nucleic acid testing on nasopharyngeal-swabbed sample, which provides high sensitivity and specificity; while rapid antigen tests have a lower sensitivity, especially in asymptomatic patients. The prevention of SARS-CoV-2 infection is based on strict infection control measures recommended for aerosol-droplet-and-contact transmission. Vaccinations against SARS-CoV-2 has shown high efficacy in reducing community transmission, hospitalisation and deaths due to severe COVID-19 disease in the general population, but immunosuppressed/haematology patients may have lower sero-responsiveness to vaccinations. Moreover, the recent emergence of new variants may require vaccine modifications and strategies to improve efficacy in these vulnerable patients. Beyond supportive care, the specific treatment is directed at viral replication control (antivirals, anti-spike monoclonal antibodies) and, in patients who need it, to the control of inflammation (dexamethasone, anti-Il-6 agents, and others). However, the benefit of all these various prophylactic and therapeutic treatments in haematology patients deserves further studies.
引用
- Cesaro S, Ljungman P, Mikulska M, et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. 2022. PMID: 35488021. doi:10.1038/s41375-022-01578-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。